Paul Hopper IP opportunists CHM VS RAD, page-8

First 8 Last

Share
Profile

Follow
Steini

12,676 Posts.

3867

30/07/22

12:54

Post #: 62828324
Share

Originally posted by Danielguda1: ↑

if you're going to be looking at RAD, I would highly suggest looking at Clarity Pharmaceuticals and Telix Pharmaceuticals and tracking their development.

A radiopharmaceutical drug will have a radioisotope and a biomarker and both of these will have an effect on the manufacturing and efficacy of the drug. Every radioisotope has a companion isotope that will be used for imaging and therapy (GA-68 is used for imaging, and Lu177 is used for therapy - Clarity uses CU64 for diagnostics and Cu67 for therapy). Radiopharmaceutical companies would usually use the same biomarker, but change the radioisotope depending on the use.

It is easy to get approval for an imaging drug and this is what Telix Pharmaceuticals has leveraged. Their recent share price ascent is due to approvals on their imaging product.

From an investor standpoint, it is less risky to bet on RAD as naturally imaging trials will be completed earlier and will have lower side effects. This will then most likely lead to an approval. Then their therapeutic products will then follow along on. Usually, imaging trials will show evidence that the biomarker they are using is able to find tumors that are not seen by the usual standard of care imaging agents. This will then provide more evidence of the ability of their therapeutic agents to find the right tumor and from there it's just a matter of whether their chosen radioisotope is able to kill the tumor.

Manufacturing is a different beast to conquer, but it is definitely less complicated than CHM's manufacturing.

Expand

Thanks for explaining what RAD is all about, appreciated.

GLTA

CHM Price at posting: 13.5¢ Sentiment: Buy Disclosure: Held
7 Upvote

0 Great analysis

Reply

Top Stories

The iron ore comeback: Can it last?

ZNC

Zenith's sale of Develin Creek delivers $975K cash, with shares up 13%

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

HAS

Hastings progressing Yangibana to production with lower costs

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

There are more pages in this discussion • 8 more messages in this thread...

First 8 Last

Add CHM (ASX) to my watchlist

(20min delay)
Last 1.4¢		Change 0.000(0.00%)		Mkt cap ! $12.67M

Open	High	Low	Value	Volume
1.4¢	1.5¢	1.4¢	$14.47K	1.027M

Buyers (Bids)

No.	Vol.	Price($)
1	391724	1.4¢

Sellers (Offers)

Price($)	Vol.	No.
1.5¢	579596	1

View Market Depth

No.	Vol.	Price($)
1	391724	0.014
13	3124769	0.013
8	1386816	0.012
3	672817	0.011
4	485142	0.010

Price($)	Vol.	No.
0.015	579596	1
0.016	735854	3
0.017	647827	3
0.018	1788235	5
0.019	987804	3

Last trade - 16.10pm 30/09/2024 (20 minute delay)

CHM (ASX) Chart

Paul Hopper IP opportunists CHM VS RAD, page-8

The iron ore comeback: Can it last?

Zenith's sale of Develin Creek delivers $975K cash, with shares up 13%

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Hastings progressing Yangibana to production with lower costs

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Paul Hopper IP opportunists CHM VS RAD, page-8

Top Stories

The iron ore comeback: Can it last?

Zenith's sale of Develin Creek delivers $975K cash, with shares up 13%

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Hastings progressing Yangibana to production with lower costs

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News